Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

First Quarter 2025 Results Key Financial Results Revenue: CA$960.9m (up 7.8% from 1Q ...

Shares Expanded Tech Sector has seen a significant rebound but remains fairly valued with a mixed technical outlook. Learn ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

IGM Financial Inc (IGIFF) reports record earnings and significant asset growth, while navigating market volatility and strategic challenges.

IGM Financial Inc. reported adjusted net earnings of $237.8 million for the first quarter, up 5.9% from the same quarter of ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the ...

May 8 - IGM Biosciences: Sanofi's termination of its 2022 collab with IGM Biosciences was the final nail in the coffin for the biotech’s research, given that it represented the last program in ...

IGM Financial Inc. reported its Q1 2025 earnings, revealing an adjusted earnings per share (EPS) of $1.00, falling short of analysts’ forecast of $1.05. The company’s revenue also missed expectations, ...